Exxel Pharma Participates in the Virtual Investor "What’s Your Story" Summer Spotlight On-Demand Conference
-
Antonio Banderas rules out retirement as he turns 65
-
Israel far right presses Netanyahu for decisive win against Hamas
-
Salah criticises UEFA for 'Palestinian Pele' tribute: 'Tell us how he died'
-
Italian Brainrot: the AI memes only kids know
-
Son Heung-min makes instant impact in LAFC debut
-
Armenians caught between hope and distrust after accord with Azerbaijan
-
Dropped Australian Test star Labuschagne plots Ashes return
-
European leaders urge more 'pressure' on Russia ahead of Trump-Putin summit
-
Defending champs Sinner, Sabalenka make winning starts in Cincinnati
-
Teen darts sensation Littler wins first World Series crown of year
-
TERRY COLE FIX IT! DEA Blocks FDA Cannabis Trials While Contaminated Marijuana Floods State Markets
-
Fleetwood clings to one-stroke PGA St. Jude lead over Rose
-
Messi to miss Miami's MLS Orlando clash
-
Nunez leaves Liverpool to join Saudi's Al-Hilal
-
Sinner storms to quick-fire opening win in Cincinnati
-
Thousands protest in Tel Aviv against Israeli govt move to expand Gaza war
-
Colombian presidential hopeful in critical condition again: doctors
-
PSG complete signing of French goalkeeper Chevalier
-
Four astronauts home from space station after splashdown
-
US star Chen will not defend Olympic figure skating gold in Italy
-
Chad court jails ex-PM, opposition leader for 20 years
-
Momentum sagging at UN plastic pollution treaty talks
-
Designer says regrets Adidas 'appropriated' Mexican footwear
-
UK arrests 365 backing banned pro-Palestine group
-
Pawol becomes first woman to umpire in MLB
-
Norris 'all good' after NFL game-stopping pre-season injury
-
Russia cautious on Armenia-Azerbaijan deal, Iran reject border corridor
-
West Ham sign Leicester goalkeeper Hermansen
-
Overcrowded French prison swelters in 'unbearable' heat
-
UK arrests 200 backing banned pro-Palestine group
-
Four astronauts leave space station for trip back to Earth
-
UN plastic pollution treaty talks floundering
-
Death toll from northwest China floods rises to 13
-
Greeks count cost of wildfire 'tragedy' near Athens
-
Historic Spanish mosque-cathedral reopens after blaze
-
Massive French wildfire contained but 'not under control'
-
Sesko completes Manchester United's new-look forward line-up
-
Manchester United sign forward Benjamin Sesko: club
-
Kyiv won't give up land, says Zelensky as US-Russia summit confirmed
-
Kyiv won't give up land, says Zelensky as US-Russia confirm summit
-
North Korea removing border loudspeakers: Seoul military
-
Gunman kills police officer near Atlanta CDC headquarters
-
Mexico discounts risk of 'invasion' after Trump order to target cartels
-
Nawaz sparks Pakistan to five-wicket ODI win over West Indies
-
Lions' Norris hospitalized after scary injury, NFL pre-season game suspended
-
Restored Nagasaki bell rings in 80 years since A-bomb
-
Putin-Trump summit: what we know so far
-
Australia settle on Marsh and Head as T20 openers
-
New York declares total war on prolific rat population
-
Patriots unveil statue honoring iconic quarterback Tom Brady
NYSE - LSE
| RBGPF | 1.7% | 73.08 | $ | |
| JRI | 0.19% | 13.435 | $ | |
| BCC | -1.34% | 82.09 | $ | |
| CMSD | 0.25% | 23.58 | $ | |
| SCS | -0.76% | 15.88 | $ | |
| VOD | 0.88% | 11.36 | $ | |
| RIO | 1.76% | 61.86 | $ | |
| SCU | 0% | 12.72 | $ | |
| RELX | -2.2% | 48 | $ | |
| RYCEF | -0.14% | 14.42 | $ | |
| NGG | -1.51% | 71.01 | $ | |
| CMSC | 0.39% | 23.05 | $ | |
| BCE | 2.34% | 24.35 | $ | |
| GSK | 0.58% | 37.8 | $ | |
| AZN | -0.69% | 73.55 | $ | |
| BP | -0.15% | 34.14 | $ | |
| BTI | 0.96% | 57.24 | $ |
Exxel Pharma Participates in the Virtual Investor "What’s Your Story" Summer Spotlight On-Demand Conference
- Video webcast now available on-demand
AURORA, CO / ACCESS Newswire / July 22, 2025 / Exxel Pharma ("Exxel" or the "Company"), a pharmaceutical company dedicated to developing novel therapeutics for the treatment of neuronal hypersensitivity disorders, today announced Soren Mogelsvang PhD, President and Chief Executive Officer and Founder of Exxel, participated in the Virtual Investor "What's Your Story" Summer Spotlight On-Demand Conference.
As part of the event, Dr. Mogelsvang dove deeper into his dedication to the Company, how he got to where he is today and provided insight into why he is so passionate about the Company's programs in development.
The on-demand video webcast is now available on virtualinvestorco.com as well as the Events page of the Company's website (exxelpharma.com).
About Exxel Pharma
Exxel Pharma is a privately held pharmaceutical company dedicated to developing novel therapeutics for the treatment of neuronal hypersensitivity disorders. The Company's lead program, EX937, is a novel, oral, patented small molecule designed to specifically and peripherally inhibit the fatty acid amide hydrolase (FAAH) enzyme. Exxel plans to launch a first-in-human Phase 1/1b study of EX937 for the treatment of refractory chronic cough, a large underserved market with no current FDA-approved therapies. In preclinical studies, EX937 demonstrated efficacy in its ability to modulate chronic cough in multiple models. Additionally, EX937 has shown to have a favorable preclinical safety profile and is expected to have no CNS side effects by being entirely excluded from the central nervous system and brain. EX937 also has the potential to be utilized across a number of high-value indications, including hyperactive bladder, peripheral neuropathic pain and migraine headaches. Exxel Pharma has a second program (ARN compounds) with the potential to treat Social Anxiety and Autism Spectrum Disorder.
Investor Contact
Jenene Thomas
Chief Executive Officer
JTC Team, LLC
T: 908.824.0775
E: [email protected]
SOURCE: Exxel Pharma, Inc.
View the original press release on ACCESS Newswire
P.Silva--AMWN